BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 20472442)

  • 1. On the inhibition of histone deacetylase 8.
    Estiu G; West N; Mazitschek R; Greenberg E; Bradner JE; Wiest O
    Bioorg Med Chem; 2010 Jun; 18(11):4103-10. PubMed ID: 20472442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors.
    Krennhrubec K; Marshall BL; Hedglin M; Verdin E; Ulrich SM
    Bioorg Med Chem Lett; 2007 May; 17(10):2874-8. PubMed ID: 17346959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.
    Tabackman AA; Frankson R; Marsan ES; Perry K; Cole KE
    J Struct Biol; 2016 Sep; 195(3):373-378. PubMed ID: 27374062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.
    Banerjee S; Adhikari N; Amin SA; Jha T
    Eur J Med Chem; 2019 Feb; 164():214-240. PubMed ID: 30594678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants.
    Marek M; Shaik TB; Heimburg T; Chakrabarti A; Lancelot J; Ramos-Morales E; Da Veiga C; Kalinin D; Melesina J; Robaa D; Schmidtkunz K; Suzuki T; Holl R; Ennifar E; Pierce RJ; Jung M; Sippl W; Romier C
    J Med Chem; 2018 Nov; 61(22):10000-10016. PubMed ID: 30347148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8.
    Stoddard SV; May XA; Rivas F; Dodson K; Vijayan S; Adhika S; Parker K; Watkins DL
    Mol Inform; 2019 Mar; 38(3):e1800080. PubMed ID: 30369061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
    Wang DF; Helquist P; Wiech NL; Wiest O
    J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies.
    Kashyap K; Kakkar R
    J Biomol Struct Dyn; 2020 Jan; 38(1):48-65. PubMed ID: 30633630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of ortho-aryl N-hydroxycinnamides as potent histone deacetylase (HDAC) 8 isoform-selective inhibitors.
    Huang WJ; Wang YC; Chao SW; Yang CY; Chen LC; Lin MH; Hou WC; Chen MY; Lee TL; Yang P; Chang CI
    ChemMedChem; 2012 Oct; 7(10):1815-24. PubMed ID: 22907916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
    Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
    Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT; Pflum MKH
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational design of selective HDAC2 inhibitors for liver cancer treatment: computational insights into the selectivity mechanism through molecular dynamics simulations and QM/MM calculations.
    Yang Y; Hu B; Yang Y; Gong K; Wang H; Guo Q; Tang X; Li Y; Wang J
    Phys Chem Chem Phys; 2021 Aug; 23(32):17576-17590. PubMed ID: 34369509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
    Debnath S; Debnath T; Bhaumik S; Majumdar S; Kalle AM; Aparna V
    Sci Rep; 2019 Nov; 9(1):17174. PubMed ID: 31748509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 Targeting.
    Hassan MM; Israelian J; Nawar N; Ganda G; Manaswiyoungkul P; Raouf YS; Armstrong D; Sedighi A; Olaoye OO; Erdogan F; Cabral AD; Angeles F; Altintas R; de Araujo ED; Gunning PT
    J Med Chem; 2020 Aug; 63(15):8634-8648. PubMed ID: 32672458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic Exploration of Methionine 274 Acting as a "Switch" of the Selective Pocket Involved in HDAC8 Inhibition: An in Silico Study.
    Yao P; Gao Q; Wang Y; Yao Q; Zhang J
    ChemMedChem; 2021 Jun; 16(12):1933-1944. PubMed ID: 33686739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.
    Vannini A; Volpari C; Filocamo G; Casavola EC; Brunetti M; Renzoni D; Chakravarty P; Paolini C; De Francesco R; Gallinari P; Steinkühler C; Di Marco S
    Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15064-9. PubMed ID: 15477595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective and nonselective HDAC8 inhibitors: a therapeutic patent review.
    Adhikari N; Amin SA; Jha T
    Pharm Pat Anal; 2018 Nov; 7(6):259-276. PubMed ID: 30632447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
    Umamaheswari A; Puratchikody A; Hari N
    Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity.
    Heimburg T; Kolbinger FR; Zeyen P; Ghazy E; Herp D; Schmidtkunz K; Melesina J; Shaik TB; Erdmann F; Schmidt M; Romier C; Robaa D; Witt O; Oehme I; Jung M; Sippl W
    J Med Chem; 2017 Dec; 60(24):10188-10204. PubMed ID: 29190092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.